



Succeeding Together

Transforming futures
in medtech & agrifood

August 2026



Legal disclaimer.


Important notice

This presentation is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any securities of The Trendlines Group Ltd. ("Company") or any of its portfolio companies nor shall it or any part of it form the basis of, or be relied on in connection with, any contract, commitment or any investment decision whatsoever in Singapore, Israel, the United States or in any other jurisdiction. The summary information herein does not purport to be complete. The information in this presentation should not be relied upon as any representation or warranty, express or implied, of the Company. No reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. The information is subject to change without notice.

The past performance of the Company is not necessarily indicative of its future performance. This presentation may contain statements that constitute forward-looking statements which involve risks and uncertainties. These statements include descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the results of business operations and financial condition, industry, environment and future events and plans of the Company. Such forward-looking statements are not guarantees of future results, performance or achievements. Actual results, performance or achievements of the Company may differ from those expressed in the forward-looking statements as a result of various factors and assumptions, such as known and unknown risks and uncertainties, including those risk factors discussed in our Offer Document dated 16 November 2015 and in our other filings with the SGXNet. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. In light of these risks and uncertainties, actual events, results and developments could differ materially from those expressed or implied by the forward-looking statements. Reliance should not be placed on these forward-looking statements, which reflect the view of the Company or its officers as of the date of this presentation only. The Company does not undertake any obligation to update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise.

None of the Company or any of its respective affiliates, advisers or representatives shall have any liability whatsoever for any loss howsoever arising, whether directly or indirectly, from any use, reliance or distribution of this presentation or its contents or otherwise arising in connection with this presentation.

Neither this presentation nor any of its contents may be used without the prior written consent of the Company.



Who **we** are.

The Trendlines Group (SGX: 42T; OTCQX: TRNLY) invests in agrifood and medtech innovative companies from seed to market. Based in Israel and Singapore, we combine capital, expertise, and partnerships to drive impactful technologies, empower entrepreneurs, and create long-term value for our investors and shareholders.

Leadership.



Haim Brosh
Executive Director &
CEO

25 years' managerial and financial experience in public and private companies.



Barak Singer
Executive VP & Head of
Healthcare

Extensive investment knowledge & experience + strong managerial and business capabilities.



Orit Alaluf Cohen
Chief Financial Officer

Broad experience in all financial functions, including accounting, internal controls, and financial reporting.



Steve Rhodes
Founder & Chair Emeritus

Trendlines' Founder; over 40 years' experience, deep understanding of investing and building companies.



Nitza Kardish PhD
Executive VP &
Head of Agrifood

Vast experience in food and agriculture technologies alongside strong business acumen.



Eric Loh
Trendlines Medical
Singapore

Over 30 years' experience establishing companies and leading their development.



Todd Dollinger
Founder & Chair Emeritus

Trendlines' Founder; over 40 years' experience developing innovative products from concept to exit.

*Haim, Nitza, Barak, Steve and Todd constitute the Company's Investment Committee.

Board of Directors.



Nehama Ronen
Independent Chair

25 years' experience in public companies. She was Director General of Israel's Ministry of Environmental Protection



Sin Boon Ann
Independent Director

30 years' experience working in the legal industry and serving as a director in many listed companies



Haim Brosh
Executive Director & CEO

25 years' managerial and financial experience in public and private companies.



Elka Nir
External Director

35 years' experience in technology management of public and private companies



Professor Low Teck Seng
Independent Director

Has served as a board member of numerous public organizations, including public companies listed on the SGX.



Sarit Zeevi
Independent & External Director

Wealth of experience in strategic investments, from selection through due diligence processes and transactional agreements

A taste of our portfolio.

31

portfolio
companies

8

agrifood

23

medtech



Portfolio cluster values.

Cluster	Fair Value of Trendlines' Share (US\$ thousands)	Non-IFRS* Value of Trendlines' Share (additional information) (US\$ thousands)
	30.06.2026	30.06.2026
Aquaculture & Animal Health	US\$ 1,336	US\$ 1,492
Crop Protection	US\$ 5,860	US\$ 11,428
Future Food & Ingredients	US\$ 15,426	US\$ 26,696
Digitization & Robotics	US\$ 3,473	US\$ 4,684
Net-Zero Technologies	US\$ 3,409	US\$ 3,409
Cardiology, Neurology & Anesthesia	US\$ 8,590	US\$ 16,055
Aesthetics	US\$ 2,661	US\$ 6,095
Gastroenterology	US\$ 10,524	US\$ 14,361
Home Healthcare	US\$ 1,138	US\$ 3,467
Spine & Orthopedics	US\$ 5,877	US\$ 11,590
Surgery	US\$ 6,154	US\$ 11,797
Urology & Women's Health	US\$ 18,958	US\$ 34,926
TOTAL	US\$ 83,406	US\$ 146,000

*See slide #20 for full explanation on Non-IFRS value.

The natural food color revolution.

A broad-spectrum of healthy plant-based colors produced via fermentation technology, using baker's yeast as a biofactory. Phytolon's high-quality and cost-effective pigments offer value for consumers, the environment and food industry.

Achievements:

- Full POC: color production & application in food products
- Commercial agreement with DSM
- Successful pilots with industry leaders including Nestlé
- R&D collaboration agreement & milestone reached with Ginkgo Bioworks
- Investment and collaboration with Rich's Product Ventures & Colorcon
- FDA approvals in progress
- Series B funding round of US\$23.6 million



Plant-based colors produced via cost-effective and sustainable fermentation of yeast

Founded 2018;
Yokne'am Illit, IL

CEO
Halim Jubran, PhD,

IP licensed from
Weizmann Institute of

Funding ~US\$40 million

Investors (see below)



ARKIN HOLDINGS



millennium
foodtech



4 more agrifood frontrunners.

8 agrifood portfolio companies



Phage-based solutions for crop disease control that target bacteria and are safe and inert to humans, animals and plants.

- Pre-commercial agreements with leading industry players
- Distribution agreement with Brazilian company **Maian Ltda.**
- Co-Development agreement with **Dole**.
- One product received regulatory approval. Four in progress.



Cultivating high quality and high value cocoa ingredients using cell culture methods, eliminating the dependence on cocoa trees for sustainable chocolate.

- Strategic investor
- Closed additional funding round
- Achieved chocolate grade cocoa butter & unveiled 1st chocolate made with it.
- POC cell growth in 80L stirred-tank bioreactor and 10L air-lift bioreactor.



Nanobody-based biological insect control to uniquely target the insect gut

- Production scale up to 1000 L
- Two active collaborations (Bayer & Nufarm)
- Raised US\$10M in Series A led by **Corteva Inc.** with Trendlines, CBG, Iron Nation & IIA.
- Successful proof of concept for AI-driven platform for protein binders that exhibit validated insecticidal activity in vivo.



Oral delivery platform for the prevention of disease in shrimp and fish

- Positive results in field study in Ecuador
- Strategic investors:



Cryotherapy treatment for urological non-muscle invasive bladder cancer (NIMBC).

A new ablative approach for the treatment of urological tissue with cryotherapy.

Achievements

- Closed US\$16.5 million investment round including strategic partner participation
- Ongoing clinical study with the flexible device showing positive results
- Future markets include Overactive Bladder



Surface cryotherapy (utilizing extreme cold) to freeze and destroy abnormal tissue

Founded 2015

CEO Eyal Kochavi

IP Submitted national phase and PCT

Funding US\$20.8 million, including grants

Investors (see below)



Strategic multinational



4 more leading medtech companies.

23 medtech portfolio companies



Minimally invasive, nonsurgical, incision-free and mesh-free repair device to treat pelvic organ prolapse (POP) in the ambulatory or office-based settings.

- Received **FDA** clearance
- Expanded sales in the US with excellent feedback from KOLs
- €8 million in funding from the prestigious EU EIC program
- Preparing for sales in Asia.



Endoscopic ultrasound fine needle biopsy system for improve, precise diagnosis of organ tumors adjacent to the gastrointestinal system.

- Received **FDA** clearance, FDA breakthrough designation & **TPT** code
- Licensing deal with HekkaBio for the Japanese market
- Began US sales and signed distribution agreement with multi-national medtech company.



Next-generation aspiration catheter for treating ischemic stroke.


- Tested at the New England Center for Stroke Research & the Jacobs Institute, Buffalo, NY
- Completed successful FIH clinical trial.
- Launched a new global clinical trial, with 35+ successful cases in Germany and Portugal.



A small, game-changing device to prevent preterm birth.

- Completed FIH safety clinical study
- Concluded FIH clinical trials in pregnant women with excellent results
- Strategic investment received

H1 2026 financial report.



Balance sheet.

Assets

(US\$'000)

Current assets	30 June 2026	31 Dec 2025
Cash and cash equivalents	830	4,817
Short-term bank deposits	4,183	110
Accounts and other receivables	1,533	2,180
Short-term loans to portfolio companies	17	270
Total current assets	6,563	7,377

Non-current assets		
Investments in portfolio companies	83,406	76,454
Accounts and other receivables	461	512
Right-of-use assets	824	1,038
Property, plant and equipment, net	364	428
Total non-current assets	85,055	78,432
Total assets	91,618	85,809

Liabilities & Equity

(US\$'000)

Current liabilities	30 June 2026	31 Dec 2025
Lease liability	221	271
Short-term loan	1,444	1,414
Trade and other payables	1,247	3,090
Total current liabilities	2,912	4,775
Long-Term liabilities		
Loans from the Israel Innovation Authority	2,731	2,587
Lease liability	928	1,079
Other long-term liabilities	15	15
Total non-current liabilities	3,674	3,681
Total liabilities	6,586	8,456
Equity		
Equity attributable to owners of the parent	84,932	78,305
Non-controlling interests	100	(952)
Total equity	85,032	77,353
Total equity and liabilities	91,618	85,809

Profit and Loss Statements.

(US\$'000)

	30 June 2026	30 June 2025
Income		
Gain/(Loss)from change in fair value of investments in portfolio companies	5,616*	(392)
Income from services to portfolio companies	113	307
Income from contracted R&D services	-	84
Financial income	81	243
Other income	100	398
Total income/(loss)	5,910	640
Expenses		
Operating, general and administrative expenses	3,446	3,394
Marketing expenses	70	67
Financial expenses	237	733
Total expenses	3,753	4,194
Net income/(loss)	2,157	(3,554)

* Including first-time valuation of the Singapore portfolio companies following the Company's transition to investment entity accounting, under which these investments are now measured at fair value.

2026 Corporate Updates.

- Raised ~S\$5.6 million for Trendlines in a private placement, including participation of an institutional investor.
- Deconsolidation of the Singapore portfolio companies where these investments are now measured at fair value.

2026 Portfolio Achievements.

- Significant portfolio progress:

- ✓ Phytolon

- FDA clearances in progress
- Completed Series B round of US\$23.6 million



- ✓ Celleste

- Unveiled first chocolate bar made from cell-cultured cocoa butter
- Raised US\$5 million



- ✓ Escala

- Commercialization in the US with growing revenues, preparing for Asian market



- ✓ Limaca

- Entered US market and signed distribution agreement with multinational medical company



2026 Portfolio Achievements.

- Significant portfolio progress:
 - ✓ Vessi
 - On going new clinical study in Spain and Israel with positive results
 - ✓ IBI-Ag
 - Successful development of AI-Driven de novo protein design platform for bioinsecticides
 - ✓ ElastiMed
 - Exclusive U.S. Distribution Agreement with Tactile Medical for commercialization in US.
 - ✓ ZygoFix
 - Performed first successful commercial cases in the US
 - ✓ EcoPhage
 - Distribution agreement for Brazil with Maian & for Mexico with Dragon
 - 1st EPA approval for first product, additional 4 product dossiers submitted to the EPA



2026 Portfolio Achievements.

- Significant portfolio progress:
- ✓ Ceretrieve
 - Ongoing new clinical study in Europe (Germany, Portugal) with successful results in more than 35 patients.
- ✓ Vensica
 - Received FDA IND clearance to initiate Phase 2 study of ViXe, its needle-free Xeomin® delivery system for overactive bladder.
- ✓ PregnanTech
 - Launched a new clinical study
- ✓ BeCapio
 - Ongoing successful clinical trial in several sites in Israel.
- ✓ AgroScout
 - Signed global contract with PepsiCo





THANK
YOU.



+972.72.260.7000 | www.trendlines.com

Notes and Disclaimer.

The non-IFRS fair value information does not represent any forecast or future performance but serves as an extra aid in evaluating our portfolio companies and investment approaches. The additional information (Non-IFRS value) which, as stated, differs from the IFRS fair value at which we carry these investments on our balance sheet, were calculated on the basis of recent portfolio company transactions (last 12 months), as follows:

1. In cases where the last transaction was through a Share Purchase Agreement (SPA) transaction, our holdings were calculated based on the pre-money valuation as the basis of the transaction, multiplied by the percentage of our holdings. Differences between preferred shares and ordinary shares were not taken into account, including regarding rights of the round including any special rights, anti-dilution clauses, etc. Some of these investments were made by shareholders who have an interest in the valuation of the portfolio company and such interests may differ from others including those of the Group.
2. In cases where the last transaction was through a Simple Agreement for Future Equity (SAFE) transaction or Convertible Loan Agreement (CLA) transaction, our holdings were calculated on the basis of the pre-defined valuation cap in the transaction, multiplied by the percentage of our holdings in the company (before conversion of the SAFE or the CLA to equity). A valuation cap may entitle investors to equity priced at the lower of the valuation cap or the pre-money valuation in a subsequent financing. The valuation cap sets the maximum price at which the convertible security will convert into equity. It is noted that SAFE or CLA transactions usually include a discount to the later round of financing. Discounts typically range from 20–30%. We also did not relate to the question as to whether the SAFE has a conversion at the end of a certain period with or without a discount and as to what type of shares the SAFE is converted.
3. In all other cases, we used generally accepted valuation methods in accordance with IFRS rules, whether cost method or the market approach. With respect to all types of transactions detailed above (SPA, SAFE, CLA), we did not take into account whether the investment was made with current investors alone or was led by them or by a new investor. Non-IFRS values have not been subject to audit or review by our external auditor and should be used cautiously as an indication of value.

The Non-IFRS values are intended to provide additional information and should not be considered in isolation or as a substitute for measures of valuation prepared in accordance with IFRS. The information contained here does not constitute, nor shall not be deemed to constitute, an offer, invitation, or inducement to invest or otherwise deal in our shares. The information contained here should be read in conjunction with our financial statements, annual report, and other announcements. Should you be contemplating investments, we urge you to take independent legal, financial, taxation, and other professional advice.

FINANCIAL STATEMENTS AND RELATED ANNOUNCEMENT::HALF YEARLY RESULTS**Issuer & Securities****Issuer/ Manager**

THE TRENDLINES GROUP LTD.

Securities

THE TRENDLINES GROUP LTD. - IL0011328858 - 42T

Stapled Security

No

Announcement Details**Announcement Title**

Financial Statements and Related Announcement

Date & Time of Broadcast

05-Aug-2026 18:55:03

Status

New

Announcement Sub Title

Half Yearly Results

Announcement Reference

SG260805OTHR9D3N

Submitted By (Co./ Ind. Name)

Sahar Farah

Designation

Joint Company Secretary

Description (Please provide a detailed description of the event in the box below - Refer to the Online help for the format)

Please see attached documents.

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Mr. Shervyn Essex, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.

Additional Details**For Financial Period Ended**

30/06/2026

Attachments

 [Trendlines - H1 2026 Announcement.pdf](#) [Trendlines H1 2026 Results Press Release.pdf](#) [Trendlines Presentation H1 2026.pdf](#)

Total size =3294K MB